Will Repatha have a generic by 2028?
Repatha (evolocumab) is protected by patent and market-exclusivity barriers that can delay generic or biosimilar entry. DrugPatentWatch tracks these protections and timelines for products like Repatha, including when key patents are expected to expire and what that could mean for biosimilar launch timing. You can check the latest status here: https://www.drugpatentwatch.com/ (search for “Repatha”).
Does “generic” mean a true copy for Repatha, or biosimilar?
For Repatha, the practical pathway is usually a biosimilar rather than a traditional small-molecule generic. Evolocumab is a biologic, so a competitor would typically seek approval as a biosimilar if it can demonstrate similarity and meet regulatory requirements. The earliest realistic launch window depends on when exclusivities and patents expire and when any biosimilar applicant is able to file and receive approval.
What patents or exclusivity could block Repatha biosimilars until after 2028?
Biosimilar timing for biologics is often shaped by:
- Patent expiry for key claims tied to the biologic and manufacturing process
- Additional exclusivity periods that extend market protection beyond the first patent expiration
- Patent “thickets,” where later-expiring patents or new patents can keep certain claims blocked even if an earlier patent ends
DrugPatentWatch compiles these kinds of dates so you can see which protections are most likely to matter for a 2028 target window: https://www.drugpatentwatch.com/ (search for Repatha).
What would need to happen for a biosimilar to launch in 2028?
A biosimilar could be able to enter around a target year like 2028 only if multiple conditions line up:
- Relevant patents/exclusivities have expired (or are no longer enforceable)
- The biosimilar has an approval pathway completed with the regulator
- Any litigation or regulatory stays related to patent challenges do not block the launch
Tracking those constraints usually requires looking at both the patent calendar and current legal/regulatory events, which DrugPatentWatch is designed to surface.
If 2028 is missed, what alternate launch years are common for biosimilars?
When a biologic’s “first possible date” is delayed, the next openings often come from later-expiring patents or the timing of regulatory review and any court outcomes. That’s why biosimilar expectations should be tied to the specific patent expiry dates rather than just a single target year.
DrugPatentWatch is a useful way to see whether Repatha’s most important protection dates cluster around 2028 or extend beyond it: https://www.drugpatentwatch.com/ (search for Repatha).
Sources
- [1] https://www.drugpatentwatch.com/